Pluripotent therapeutic compositions and uses thereof

a therapeutic composition and a technology of a composition, applied in the direction of bacteria material medical ingredients, dispersed delivery, peptide/protein ingredients, etc., can solve the problem that no active treatment is offered that can save the patient, and achieve the effect of reducing reducing the dosage of medication, and avoiding the risk of allergic reactions

Inactive Publication Date: 2009-11-05
IMMUNOPATH PROFILE INC A CORP OF PA
View PDF37 Cites 46 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0131](5) Sourcing has avoided the risk of allergic reaction by avoiding protein or substances that would cross match the patient's genetic code,
[0132](6) May be used freely with other medication to reduce their significant risk and dosage of medication.

Problems solved by technology

It describes the clinical effects that are commonly observed, and indicates what treatments may be helpful.Unfortunately, in too many instances, including nuclear radiation, no active treatment is offerable that can save the patient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pluripotent therapeutic compositions and uses thereof
  • Pluripotent therapeutic compositions and uses thereof
  • Pluripotent therapeutic compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Example of Multi-Center Study

[0406]Within three to six weeks of initiation of this treatment using the compositions of the invention approaching 95% of Crohn's disease (CD) and pediatric Crohn's disease (PCD) patients are being studied in double-blind, placebo-controlled multi-center including 35 radiographically tagged inflammatory neutrophile permeability studies as well as the open study are able to discontinue the immune suppression therapy.

[0407]Remarkably, the discontinuance is not associated with relapse for a period of at least six months. More than 95% are maintained in the disease-free state for as long as one year. Growth arrest and puberty suppression are overcome within six weeks in more than 20 patients with a predictable efficacy of over 95% in 150 patients (⅓ of 450 being studied, (PCD cases treated exceed 200 patients). Controlled in-vitro tissue culture studies of biopsied Crohn's tissue evidences significant (approaching more than 95%) reduction in inflammatory me...

example 2

[0411]Congenital biliary atresia (CBA) is a rare fatal (prior to treatment with this invention) disease without liver transplant, with a U.S. incidence of only 300 cases per year (approximately 1 per 1 million of U.S. population) with symptoms occurring at onset of infancy that include: poor appetite, poor food intake, extreme jaundice, (21 mgm percent bilirubin, with biliary obstruction further confirmed by an abnormal dye excretion study. stools were gray, acholic, lacking normal stool bilirubin color), lassitude, weight loss, failure to thrive, abnormal liver function tests, abnormal liver ultrasound, and abnormal biopsy.

[0412]Therapy with the compositions of the invention in a CBA patient using components No. 1 and No. 2 re-established organ function, stimulated tissue healing and tissue protein synthesis concurrent with significant anti-inflammatory activity, clearance of all abnormal liver function, and averted the required for a liver transplant.

[0413]Components No. 1 and No....

example 3

Crohn's Disease, (CD) Case Report, Part (a)

[0415]A 71 year old female patient with more than 3 decades of Crohn's disease whose symptoms included diarrhea, constipation, severe bouts of abdominal pain and fever, generalized aching, extreme fatigue, nausea, food and dairy intolerance, increased sedimentation rate, recently had a flare up of the Crohn's disease. Response from 4 mgm of corticosteroid, once daily was unsatisfactory. Corticosteroid dosing was then increased to 4 times daily for acute flare ups.

[0416]The patient received a composition comprising 5 to 25 grams of L-amino acids and glycine, lecithin (phospholipid-PC), and extracellular matrix components comprising collagen, proteoglycan aggregate complex of cartilage and chondrotin sulfate (shark cartilage 740 mg. per capsule, 4 capsules twice daily). Symptoms of severe abdominal pain and diarrhea, and the flare-up were cleared within 24 hours. The improvement continued over the next few weeks, and the patient responded to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
viscosityaaaaaaaaaa
molar ratioaaaaaaaaaa
viscosityaaaaaaaaaa
Login to view more

Abstract

Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self healing effect promoting tissue healing and tissue regeneration. Not only does it maintain good health but also it has been observed that the patient's blood is withdrawn from the patient and applied to the ulcer has healing qualities. Cartilage placed in a wound promotes and accelerates wound healing. The anabolic biochemical and biophysical equivalent of tissue has been found in these embodiments to have the same pharmacologic qualities, when devoid of genetic DNA mismatch and other catabolic factors including the catabolic effects of microorganism overgrowth that lacks pro-biotic qualities. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. application Ser. No. 10 / 868,697, filed Jun. 14, 2004, which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 60 / 577,120, filed tune 4, 2004; 60 / 557,584; filed Mar. 29, 2004; 60 / 550,797, filed Mar. 5, 2004; 60 / 478,565, filed Jun. 12, 2003; 60 / 493,237, filed Aug. 6, 2003; and 60 / 523,936, filed Nov. 21, 2003. These applications are all hereby incorporated by reference in their entireties, including all figures, formulae, references, amino acid and nucleic acid sequences, and tables.[0002]This application is a continuation-in-part of U.S. application Ser. No. 10 / 868,697, filed Jun. 14, 2004, which is a continuation-in-part of application Ser. No. 10 / 765,664, filed Jan. 26, 2004 which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 60 / 442,278, filed Jan. 24, 2003; 60 / 447,779, filed Feb. 13, 2003; 60 / 448,003, filed Feb. 18, 2003; 60 / 448,497, filed Feb. 19,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/74A61K35/12A61K35/34A61K35/741
CPCA61K9/0095A61K38/54A61K31/737A61K35/741A61K38/39A61K31/726A61K36/87A61K35/744A61K35/60A61K31/198A61K31/202A61K2300/00
Inventor GIRSH, LEONARD S.
Owner IMMUNOPATH PROFILE INC A CORP OF PA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap